GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSTO:ULTIo) » Definitions » Issuance of Debt

Ultimovacs ASA (OSTO:ULTIO) Issuance of Debt : kr0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Issuance of Debt?

Ultimovacs ASA's Issuance of Debt for the three months ended in Sep. 2024 was kr0.00 Mil.

Ultimovacs ASA's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.00 Mil.


Ultimovacs ASA Issuance of Debt Historical Data

The historical data trend for Ultimovacs ASA's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Issuance of Debt Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only - - - - -

Ultimovacs ASA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ultimovacs ASA Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultimovacs ASA Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA Headlines

No Headlines